Heron Therapeutics | HRTX - Current Liabilities


Heron Therapeutics reported $92.14M in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
ALKERMES USD 651.93M 10.16M Sep/2026
Alnylam Pharmaceuticals USD 2.06B 550.49M Sep/2026
Amarin USD 175.14M 10.94M Sep/2026
ANI Pharmaceuticals USD 328.72M 45.06M Sep/2026
Anika Therapeutics USD 22.15M 1.18M Jun/2026
Arrowhead Research USD 283.35M 11.87M Jun/2026
Eisai JPY 393.64B 53.39B Jun/2026
Emergent BioSolutions USD 651.3M 12.7M Dec/2023
GlaxoSmithKline GBP 20.72B 814M Sep/2026
Heron Therapeutics USD 92.14M 1.63M Jun/2026
Insmed USD 596.57M 157.83M Sep/2026
Ligand Pharmaceuticals USD 500.57M 453.83M Sep/2026
Merck USD 28.8B 1.07B Sep/2026
Nektar Therapeutics USD 57.71M 4.17M Mar/2026
Neurocrine Biosciences USD 984.6M 110.1M Sep/2026
Omeros USD 85.5M 2.28M Jun/2025
Pacira USD 126.1M 4.08M Sep/2026
Regeneron Pharmaceuticals USD 6.2B 671.5M Sep/2026
Roche Holding CHF 28.85B 846M Jun/2026
Sangamo BioSciences USD 47.66M 1.9M Jun/2025
Ultragenyx Pharmaceutical USD 389M 38M Sep/2026
Veracyte USD 84.21M 21.47M Sep/2026
Vertex Pharmaceuticals USD 5B 1.06B Sep/2026